ArticleBioinformatics (Oxford, England)2025
CATH-ddG: towards robust mutation effect prediction on protein-protein interactions out of CATH homologous superfamily.
Article in Bioinformatics (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- PreFold-dG: estimating binding affinity of protein-protein interaction from intermediate representations of protein folding model.Bioinformatics (Oxford, England) · 2026Article
- USP-ddG: a unified structural paradigm with data efficacy and mixture-of-experts for predicting mutational effects on protein-protein interactions.Bioinformatics (Oxford, England) · 2026Article
- Beyond Random Splits: Assessing the Generalization of Graph and Vector Models for WT-Structure-Only Drug Resistance Prediction under Protein-Disjoint Evaluation.Computational and structural biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
motivationProtein-protein interactions (PPIs) are fundamental aspects in understanding biological processes. Accurately predicting the effects of mutations on PPIs remains a critical requirement for drug design and disease mechanistic studies. Recently, deep learning models using protein 3D structures have become predominant for predicting mutation effects. However, significant challenges remain in practical applications, in part due to the considerable disparity in generalization capabilities between easy and hard mutations. Specifically, a hard mutation is defined as one with its maximum TM-score <0.6 when compared to the training set. Additionally, compared to physics-based approaches, deep learning models may overestimate performance due to potential data leakage.
resultsWe propose new training/test splits that mitigate data leakage according to the CATH homologous superfamily. Under the constraints of physical energy, protein 3D structures, and CATH domain objectives, we employ a hybrid noise strategy as data augmentation and present a geometric encoder scenario, named CATH-ddG, to represent the mutational microenvironment differences between wild-type and mutated protein complexes. Additionally, we fine-tune ESM2 representations by incorporating a lightweight nonlinear module to achieve the transferability of sequence co-evolutionary information. Finally, our study demonstrates that CATH-ddG framework provides enhanced generalization by outperforming other baselines on non-superfamily leakage splits, which plays a crucial role in exploring robust mutation effect regression prediction. Independent case studies demonstrate successful enhancement of binding affinity on 419 antibody variants to human epidermal growth factor receptor 2 (HER2) and 285 variants in the receptor-binding domain (RBD) of SARS-CoV-2 to angiotensin-converting enzyme 2 (ACE2) receptor. AVAILABILITY AND IMPLEMENTATION: CATH-ddG is available at https://github.com/ak422/CATH-ddG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.